MICHAEL JAMES OVERMAN to Vascular Endothelial Growth Factor A
This is a "connection" page, showing publications MICHAEL JAMES OVERMAN has written about Vascular Endothelial Growth Factor A.
Connection Strength
0.203
-
The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013; 8(10):e77117.
Score: 0.071
-
Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res. 2011 Oct 01; 17(19):6130-9.
Score: 0.062
-
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 11; 11(11):2738-2747.
Score: 0.030
-
Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Invest New Drugs. 2015 Aug; 33(4):977-84.
Score: 0.020
-
Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. Ann Surg Oncol. 2015 Aug; 22(8):2578-84.
Score: 0.019